Clinical Trials Logo

Clinical Trial Summary

The primary objective is to evaluate the safety and tolerability of single ascending dose of Y-2 sublingual tablets in healthy male and female adult subjects. The secondary objective is to characterize the single-dose pharmacokinetics of Y-2 sublingual tablets in healthy male and female adult subjects.

Clinical Trial Description

This study will be a single-center, single ascending dose study in healthy male and female subjects. A total of 24 subjects, 4 cohorts of 6 subjects each, will be enrolled in this study. All of the 6 subjects in each cohort will receive a single dose of Y-2 sublingual tablet on a single occasion. Prior to taking the drug and after taking the drug at 5 min to 24 h, venous blood from all subjects will be collected at different time points for PK analysis. After dosing, safety and tolerability data for each cohort will be evaluated. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT03495206
Study type Interventional
Source Yantai YenePharma Co., Ltd.
Contact David Z. Wang, M.D.
Phone (309) 624-9500
Status Not yet recruiting
Phase Phase 1
Start date April 2018
Completion date October 2018

See also
  Status Clinical Trial Phase
Recruiting NCT03132558 - Contrast Induced Acute Kidney in Patients With Acute Stroke N/A
Recruiting NCT02541578 - Physiological Complexity of Gait Over the First Six Months Post Stroke N/A
Recruiting NCT02893631 - Assessment of Hemostasis Disorders in rtPA-treated Patients Requiring Endovascular Treatment for Ischemic Stroke N/A
Active, not recruiting NCT02274727 - Biomarker Signature of Stroke Aetiology Study: The BIOSIGNAL-Study
Recruiting NCT02225730 - Imaging Collaterals in Acute Stroke (iCAS) N/A
Terminated NCT01705353 - The Role of HMGB-1 in Chronic Stroke N/A
Active, not recruiting NCT01581502 - SAMURAI-NVAF Study: Anticoagulant Therapy for Japanese Stroke Patients With Nonvalvular Atrial Fibrillation (NVAF) N/A
Completed NCT01182818 - Fabry and Stroke Epidemiological Protocol (FASEP): Risk Factors In Ischemic Stroke Patients With Fabry Disease N/A
Completed NCT00761982 - Autologous Bone Marrow Stem Cells in Middle Cerebral Artery Acute Stroke Treatment. Phase 1/Phase 2
Completed NCT00535197 - Autologous Bone Marrow Stem Cells in Ischemic Stroke. Phase 1/Phase 2
Terminated NCT00132509 - FRALYSE Trial: Comparison of the Classical Rt-PA Procedure With a Longer Procedure in Acute Ischemic Stroke Phase 2
Recruiting NCT03235271 - Pilot Study of Acute Stroke Using the Brainpulseâ„¢
Recruiting NCT03324321 - Feasibility of Improving Cerebral Autoregulation in Acute Intracerebral Haemorrhage N/A
Recruiting NCT02989376 - Carotid Duplex Ultrasound for Selecting Patients for Endovascular Thrombectomy in Acute Stroke Patients N/A
Recruiting NCT02207023 - Healthy Lifestyles After Stroke N/A
Completed NCT01957774 - THR-18's Pharmacokinetics and Pharmacodynamics in Subjects With Acute Ischemic Stroke Treated With tPA Phase 2
Recruiting NCT02002390 - Efficacy and Safety of FTY720 for Acute Stroke Phase 2
Active, not recruiting NCT01327989 - Solitaire FR Thrombectomy for Acute Revascularisation N/A
Completed NCT00123305 - Intravenous Administration of Microplasmin for Treatment of Acute Ischemic Stroke Phase 2
Recruiting NCT03245957 - HDL Dysfunction During the Acute Stage of Stroke N/A